TOKYO, Oct. 29, 2025 -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.73 billion (USD 11.6 million1) in four R&D projects for the development of diagnostics and a vaccine for tuberculosis (TB), neglected tropical diseases (NTDs), and malaria.2 Investment of JPY 390 Million (USD 2.6 million1) to Advance a Novel Rapid Diagnostic for TuberculosisTuberculosis (TB) remains one of the world's most devastating infectious diseases, affecting over 10 million people and causing 1.3 million deaths annually.3 In resource-limited
[ 메디채널 김갑성 기자 ] - Strategic MOU enhances market access and extends reach to over 900 hospitals across the region SEOUL, South Korea, Oct. 29, 2025 -- VUNO Inc., a global medical AI company, announced today that it has signed a strategic Memorandum of Understanding (MOU) with Contextflow, an Austrian imaging AI company, and Mesalvo, a German hospital information system (HIS) provider, to jointly advance into the European market with its AI-based cardiac arrest prediction solution, VUNO Med®–DeepCARS®. The MOU was signed on October 27 during a local meeting held in conju
RESTON, Va., Oct. 29, 2025 -- A breakthrough in color measurement is on the horizon. This November, HunterLab will unveil the Agera L2, the next generation in spectrophotometric innovation that will once again redefine how the world measures and perceives color. The Agera L2 represents a major advance in HunterLab's ongoing mission to align instrumental color measurement with the way the human eye perceives color. Designed for precision, speed, and usability, it introduces technologies that eliminate the remaining gap between calculated color values and visual assessment.
HONG KONG, Oct. 29, 2025 -- Charming Medical Limited (Nasdaq: MCTA) (the "Company"), a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products, today announced, in connection with its previously announced initial public offering (the "Offering") of 1,600,000 Class A ordinary shares, par value $0.0001 per share (the "Class A Ordinary Shares") at a price of $4.00 per share (the "Public Offering Price"), Cathay Securities, Inc., the representative of the underwriters (the "Representative") of the Offering, h
Deepening collaboration with NVIDIA to bring NVIDIA Vera Rubin NVL144 and NVIDIA Vera Rubin CPX platforms to market in 2026 to provide more than 3x AI attention acceleration vs. Blackwell Ultra Powered by Data Center Building Block Solutions®, Supermicro introduces a compact 2OU NVIDIA HGX B300 8-GPU system with OCP-based rack-scale design supporting up to 144 GPUs in a single rack Supermicro's San Jose, CA manufacturing ensures solutions are developed, constructed, and validated in the USA, are TAA-compliant, and are Buy American Act-capable Supporting a full-stack NVIDIA
WASHINGTON, Oct. 29, 2025 -- A recent article published in the American Journal of Primatology criticizes work relied upon by the International Union for Conservation of Nature (IUCN) in its latest determination concerning long-tailed macaque monkeys (Macaca fascicularis). The article, entitled "Estimating the Abundance of Widely Distributed Primates," concludes that scientific work adopted by the IUCN is "flawed and results in a serious underestimate of the global abundance of the species." The article goes on to state that such population estimates are bas
일본에 본사를 둔 닛폰신야쿠, 라이프스피어 멀티비질런스를 새로운 사례 처리 데이터베이스로 선정 도쿄, 2025년 10월 29일 -- 생명과학 분야를 선도하는 AI 주도 기술 회사이자 라이프스피어(LifeSphere®)를 개발한 아리스글로벌(ArisGlobal)은 오늘 닛폰신야쿠(Nippon Shinyaku, Ltd.)®가 자사의 라이프스피어 세이프티(LifeSphere Safety)® 플랫폼을 선택했다고 발표했다. 닛폰신야쿠는 국내외 안전성 관련 절차를 일원화하고자 글로벌 통합 데이터베이스와 업무 효율화를 모색했다. 이 회사는 검증된 자동화 기술, 일본 등 전 세계에서 오랫동안 축적한 구현 및 변경 관리 성공 사례, 그리고 전 세계의 다양한 규제와 일본 고유의 규정을 동시에 준수할 수 있는 능력을 고려해 라이프스피어를 선택했다. 라이프스피어 세이프티 플랫폼은 다음과 같은 솔루션으로 구성되어 있다. 라이프스피어 멀티비질런스(LifeSphere® MultiVigilance) – 전 세계의 규정에 맞게 확장할 수 있는 사례 처리 및 안전 데이터 관리용 토털 솔루션이
최첨단 시설로 회사의 글로벌 연구 개발 역량 확장 더 우즈랜드, 텍사스, 2025년 10월 29일 -- 세계적인 고성능 첨가제, 생산 공정 솔루션, 의약품, 유기화학물 중간체 개발사이자 제조사인 SI 그룹(SI Group)이 영국 포 애쉬즈에 유럽 혁신 센터(European Innovation Centre, EIC)를 공식 개소했다고 발표했다. 이번 개소는 SI 그룹의 글로벌 혁신 네트워크 확장을 의미하며, 연구개발(R&D)과 응용기술 개발 역량을 강화해 전 세계 고객에게 보다 나은 서비스를 제공할 것으로 기대된다. 새로운 최첨단 시설은 다양한 연구 활동을 지원하기 위한 첨단 장비와 자원을 갖추고 있다. 플라스틱 및 고무 응용 개발과 분석 특성화에 중점을 둔 이 센터는 고객 및 업계 리더와의 협력을 통해 기술적 과제를 해결하고 지속 가능한 혁신을 추진하는 허브 역할을 수행하게 된다. 영국의 새로운 포 애시즈 시설 외에도 SI 그룹은 다음과 같은 지역에서도 혁신 센터를 운영하고 있다. 미국 텍사스주 휴스턴 미국 뉴욕주 로테르담 정션, 뉴욕, 미국 미국 웨스트버지니아주 모건타운
BEIJING, Oct. 28, 2025 -- Beijing Tsingke Biotech Co., Ltd., a pioneer in molecular manufacturing, showcased its next-generation integrated platforms at the 2025 Festival of Biologics in Basel. Over 2,000 biotech experts from 50 countries attended, witnessing Tsingke's AI-driven solutions for gene and RNA design, antibody discovery, and scalable GMP-grade biologics production, highlighting the company's role in bridging laboratory research with industrial-scale manufacturing. Industry Trends Highlighted: Early-stage developability: process validation begins during discovery
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 28, 2025 -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the launch of its first fully human Generative AI HCAb (Heavy Chain-Only Antibody) Model powered by its Hu-mAtrIx™ AI platform, built upon the Harbour Mice® platform. This platform establishes a closed-loop process integrating AI design, intelligent screening, and wet-lab validation. The announcement was made at